Alpha1 Antitrypsin Deficiency

Study Outline

This study is:

• Approximately 3 years
• Phase III
• Safety and Efficacy of two dose regimes of the study drug
• Weekly infusions

To find out if this trial is suitable for you please register below, or contact our Clinical Trials Team at admin@resphealth.uwa.edu.au or phone 6151 0888.

Eligibility & Requirements

• 18 – 70 years old
• Diagnosis of Alpha1 Antitrypsin Deficiency with evidence of emphysema
• No flare up of the chest in the last 5 weeks prior to the first visit
• No cancer in last 5 years

What's Involved

• You will be required to come once a week for 3 years for treatment including health checks to the Institute for Respiratory Health at Level 2, 6 Verdun Street, Nedlands WA 6009
• CT scans of your lungs will be required on 5 occasions throughout the trial